semaglutide nejm weight loss Tirzepatide vs for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% at 72 wks • Semaglutide: −13.7% • Greater waist reduction Tirzepatide as Compared with Semaglutide

The specific physiological mechanisms of ejaculatory dysfunction remain unclear, and there is a lack of research on how neuropathy specifically affects the ejaculation process

Combination treatment requires closer monitoring and patient engagement

they provide a glimpse into the next frontier of obesity care

CrossRef Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya Naunyn-Schmiedeberg's Archives of Pharmacology.2024